About Us Chronic Pain Our Brands Investors Contact Analyst Coverage KRC Insights Analyst Report Please note that any opinions, estimates or forecasts regarding NeuPath's performance made by this analyst is theirs alone and does not represent opinions, forecasts or predictions of NeuPath or its management. NeuPath does not by its reference above or distribution imply its endorsement of or concurrence with such information, conclusions or recommendations. Careers | Contact Terms of Use

About Us Chronic Pain Our Brands Investors Contact Board of Directors Dianne Carmichael - Director (Chair) Jolyon Burton - Director Daniel Chicoine - Director Sasha Cucuz - Director Dan Legault - Director Grishanth Ram - Director Joseph Walewicz - Director Careers | Contact Terms of Use

About Us Chronic Pain Our Brands Investors Contact Financial Reporting NeuPath regulatory filings can be found on the Sedar website. Latest Financial Reports Q3 2021 News Release Financial Statements MD&A 2021 Financial Statements Q1 / Q2 MD&A Q1 / Q2 News Release Q1 / Q2 2020 Financial Statements Q1 / Q2 / Q3 / Q4 MD&A Q1 / Q2 / Q3 / Q4 News Release Q1 / Q2 / Q3 / Q4 Annual Information Form PDF Management Information Circular PDF Careers | Contact Terms of Use

About Us Chronic Pain Our Brands Investors Contact Shareholder Information NPTH.V TSX VENTURE EXCHANGE SHARE STRUCTURE Share Capital as at September 30, 2021 Common Shares Outstanding - Basic/Diluted - 46.5 million Stock Quote The NeuPath common shares started trading on the TSX Venture Exchange on July 6, 2020. Registered shareholders with questions regarding share certificates, change of address for your account or share transfers should contact: Transfer Agent TSX Trust Company 301-100 Adelaide Street West Toronto, ON M5H 4H1 (416) 361-0930 tmxeinvestorservices@tmx.com Independent Auditors Ernst & Young LLP 100 Adelaide Street West Toronto, ON M5J 2T6 Contact To receive an investor package or for general investor enquiries please complete the form on our Contact page. Subscribe By providing your e-mail address, you are consenting to receive press releases and other information concerning NeuPath Health Inc. and its affiliates and partners. You may withdraw your consent at any time. Careers | Contact Terms of Use